The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in
Sponsorship statement:
Funding for this educational activity has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found below:
  • Sponsored by Pfizer Limited. Pfizer has had no involvement or influence over the content of this educational material.
  • This activity has been funded by Bayer plc. through a reactive sponsorship. Bayer plc. had no involvement with the development of this material.
Pfizer_Logo_Color_CMYK
Logo_Bayer

Referral and diagnosis of suspected cardiac amyloidosis

24 October 2025
Available for 1 CPD point(s)

Masterclass

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Assessment of a patient with suspected amyloidosis requires a careful diagnostic workup, including cardiac imaging to identify amyloid infiltration in heart tissue that could lead to diastolic dysfunction and heart failure. In this Masterclass, clinicians and scientists from the National Amyloidosis Centre describe the laboratory tests and imaging techniques used to make an accurate diagnosis.
Learning objectives
  • To understand the imaging techniques used to diagnose and monitor cardiac amyloidosis, and the key features seen on these studies
  • To know all the information and test results that should be included in a referral for a patient suspected of having cardiac amyloidosis
  • To understand the role of genetic testing, immunohistochemistry and proteomics in the diagnostic pathway
Speakers:

Professor Marianna Fontana Deputy Clinical and Research Lead
Janet Gilbertson Head of Histology/Proteomic Service and Laboratory Manager
Julian Gillmore NAC Research Lead
David Hutt Lead Nuclear Medicine Technologist
Dr Ana Martínez-Naharro Consultant Cardiologist
Dr Dorota Rowczenio Head of Genetic Service
Angelique Smit Lead Clinical and Research Nurse

Categories

Tags

© 2025 Medinews Cardiology Ltd, a wholly-owned subsidiary of OmniaMed Communications Ltd   |   Privacy & cookies policy   |   Terms & conditions

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.